The Sabin Vaccine Institute today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) had awarded it a multi-year contract with funding potential for up to $214 million to advance the development and production of Ebola Sudan and Marburg virus diseases vaccines.
As of January 12, 2023, no licensed vaccines against Ebola Sudan and Marburg viruses exist.
However, if approved, these vaccines could be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
Read More
